16 research outputs found

    Neonatal Hyperbilirubinemia. Evidence for a Role of the Erythrocyte Enzyme Activities Involved in the Detoxification of Oxygen Radicals

    Full text link
    Determinations of erythrocyte enzyme scavengers of oxygen radicals (glutathione-peroxidase, superoxide-dismutase and catalase) and determinations of erythrocytes age-dependent glycolytic activities (glucose-6-phosphatedehydrogenase, pyruvate-kinase and glucose-phosphate-isomerase) were carried out in cord blood and in the blood taken on the 4th day of life in 152 newborn infants with different peak bilirubin levels. The enzyme activities scavenging oxygen radicals, glutathione-peroxidase and superoxide-dismutase were significantly lower in infants with peak bilirubinemia higher than 214 ÎŒmol/l, compared to less-jaundiced neonates, both at birht and on the 4th day of life; their values correlated negatively with peak bilirubinemia at birth and on the 4th day of life. Glycolytic age-dependent enzyme activities were significantly higher in more jaundiced newborn infants only on the 4th day of life, when their values correlated positively with peak bilirubinemia. The results of this investigation suggest that a deficiency of factors protecting from oxygen toxicity, may play a role in the development of neonatal hemolysis and jaundice

    Polypharmacy among older adults with dementia compared with those without dementia in the United States

    Full text link
    BACKGROUND/OBJECTIVES: In older persons with dementia (PWD), extensive medication use is often unnecessary, discordant with goals of care, and possibly harmful. The objective of this study was to determine the prevalence and medication constituents of polypharmacy among older PWD attending outpatient visits in the US. DESIGN: Cross-sectional analysis. SETTING & PARTICIPANTS: PWD and persons without dementia (PWOD) age ≄65 years attending outpatient visits recorded in the nationally representative National Ambulatory Medical Care Survey (NAMCS), 2014-2016. MEASUREMENTS: PWD were identified as those with a diagnosis of dementia on the NAMCS encounter form and/or those receiving an anti-dementia medication. Visits with PWD and PWOD were compared in terms of sociodemographic, practice/physician factors, comorbidities, and prescribing outcomes. Regression analyses examined the effect of dementia diagnosis on contributions by clinically relevant medication categories to polypharmacy (defined as being prescribed ≄5 prescription and/or non-prescription medications). RESULTS: The unweighted sample involved 918 visits for PWD and 26,543 visits for PWOD, representing 29.0 and 780 million outpatient visits. PWD had a median age of 81 and on average had 2.8 comorbidities other than dementia; 63% were female. The median number of medications in PWD was 8 compared to 3 in PWOD (p<0.001). After adjustment, PWD had significantly higher odds of being prescribed ≄5 medications (AOR 3.0; 95% CI: 2.1-4.3) or ≄10 medications (AOR 2.8; 95% CI: 2.0-4.2) compared to PWOD. The largest sources of medications among PWD were cardiovascular and central nervous system medications; usage from other categories was generally elevated in PWD compared to PWOD. PWD had higher odds of receiving at least one highly sedating or anticholinergic medication (AOR 2.5; 95% CI: 1.6-3.9). CONCLUSION: In a representative sample of outpatient visits, polypharmacy was extremely common among PWD, driven by a wide array of medication categories. Addressing polypharmacy in PWD will require cross-cutting and multidisciplinary approaches
    corecore